Evaluation of the immunogenicity of a recombinant glycoprotein-based Chandipura vaccine in combination with commercially available DPT vaccine

Vaccine

Volumn 28, Issue 6, 2010, Pages 1463-1467

  Venkateswarlu, C H ^a   Arankalle, V A ^a  

^a NATIONAL INSTITUTE OF VIROLOGY   (India)

Author keywords

Baculovirus expression system; Chandipura virus; CHP DPT combination vaccine; Commercially available DPT vaccine; Recombinant G protein based vaccine

Indexed keywords

CHANDIPURA VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; UNCLASSIFIED DRUG; VIRUS RNA; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHANDIPURA VIRUS; CONTROLLED STUDY; DRUG EFFICACY; ENCEPHALITIS; FEMALE; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHABDOVIRUS; SEROCONVERSION; VIRUS STRAIN;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BRAIN; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; FEMALE; MICE; RHABDOVIRIDAE INFECTIONS; SURVIVAL ANALYSIS; VACCINES, COMBINED; VACCINES, SUBUNIT; VACCINES, SYNTHETIC; VESICULOVIRUS; VIRAL VACCINES;

EID: 75249101436     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.11.072     Document Type: Article

References (13)

1. Bhatt P.N., and Rodrigues F.M. Chandipura: a new Arbovirus isolated in India from patients with febrile illness. Indian J Med Res 55 (1967) 1295-1305
2. Rodrigues J.R., Singh P.B., Dave D.S., Prasad R., Ayachit V., and Shaik B.H. Isolation of Chandipura virus from the blood in acute encephalopathy syndrome. Indian J Med Res 77 (1983) 303-307
3. Dhanda V., Rodrigues F.M., and Ghosh S.N. Isolation of Chandipura virus from sandflies in Aurangabad. Indian J Med Res 58 (1970) 179-180
4. Rao B.L., Basu A., Wairagkar N.S., Gore M.M., Arankalle V.A., Thakare J.P., et al. A large outbreak of acute encephalitis with high fatality rate in children in Andhra Pradesh, India, in 2003, associated with Chandipura virus. Lancet 364 (2004) 869-874
5. Chadha M.S., Arankalle V.A., Jadi R.S., Joshi M.V., Thakare J.P., Mahadev P.V., et al. An outbreak of Chandipura virus encephalitis in the eastern districts of Gujarat state, India. Am J Trop Med Hyg 73 (2005) 566-570
6. Tandale B.V., Tikute S.S., Arankalle V.A., Sathe P.S., Joshi M.V., Ranadive S.N., et al. Chandipura virus: a major cause of acute encephalitis in children in North Telangana, Andhra Pradesh, India. J Med Virol 80 (2008) 118-124
7. Venkateswarlu C.H., and Arankalle V.A. Recombinant glycoprotein based vaccine for Chandipura virus infection. Vaccine 27 (2009) 2845-2850
8. Reed L.J., and Muench H.A. Simple method of estimating fifty per cent endpoints. Am J Hyg 27 (1938) 493-497
9. Kumar S., Jadi R.S., Anakkathil S.B., Tandale B.V., Mishra A.C., and Arankalle V.A. Development and evaluation of a real-time one step reverse-transcriptase PCR for quantitation of Chandipura virus. BMC Infect Dis 8 (2008) 168
10. Caulfield M.J., Smith J.G., Wang S., Capen R.C., Blondeau C., Lentsch S., et al. Immunogenicity of a hexavalent combination vaccine in rhesus monkeys. Vaccine 19 (2000) 902-907
11. Esposito S., Faldella G., Giammanco A., Bosis S., Friscia O., Clerici M., et al. Long-term pertussis-specific immune responses to a combined diphtheria, tetanus, tricomponent acellular pertussis and hepatitis B vaccine in pre-term infants. Vaccine 20 (2002) 2928-2932
12. Mallet E., Matisse N., Mathieu N., Langue J., Boisnard F., Soubeyrand B., et al. Antibody persistence against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) in 5-6-year-old children after primary vaccination and first booster with a pentavalent combined acellular pertussis vaccine: immunogenicity and tolerance of a tetravalent combined acellular pertussis vaccine given as a second booster. Vaccine 22 (2004) 1415-1422
13. Black S., Friedland L.R., Schuind A., Howe B., and GlaxoSmithKline DTaP-IPV Vaccine Study Group. Immunogenicity and safety of a combined DTaP-IPV vaccine compared with separate DTaP and IPV vaccines when administered as pre-school booster doses with a second dose of MMR vaccine to healthy children aged 4-6 years. Vaccine 24 (2006) 6163-6171